In the unknown universe of rare or infrequent diseases, many go unnoticed despite their significant impact on the lives of those who suffer from them. One such condition is Immune Thrombocytopenia (ITP), a disease that affects thousands of people each year around the world. Although its name is unfamiliar to many people, ITP can have serious and long-lasting consequences.
To better understand this disease, we have the testimony of Dr. Cristina Pascual, president of the Spanish Immune Thrombocytopenia Group (GEPTI), a working group of the Spanish Society of Hematology and Hemotherapy (SEHH) and hematologist at the Gregorio Marañón General University Hospital. Dr. Pascual offers a detailed view of what it means to live with ITP, addressing both the physical and emotional aspects that affect patients.
What is immune thrombocytopenia (ITP)?
Immune thrombocytopenia, commonly known as ITP, is a rare autoimmune disease that affects the blood, in which the body’s own immune system attacks and destroys platelets—essential blood components responsible for clotting. This condition occurs due to a loss of tolerance in the immune system, which mistakenly identifies platelets as foreign elements and destroys them. Dr. Pascual explains that “platelets are essential for preventing bleeding, and when their number decreases significantly, the risk of spontaneous bleeding increases.” Medically speaking, ITP is diagnosed when the platelet count falls below 100,000 and cannot be attributed to other causes, such as infections or side effects of medications.
Differences with other similar diseases
One of the common challenges in understanding ITP is its confusion with other autoimmune diseases that also affect platelets, such as Acquired Thrombotic Thrombocytopenic Purpura (ATTP). Although both conditions are characterized by a low platelet count, Dr. Pascual emphasizes that “ITP and aTTP are distinct diseases with different treatment approaches. While ITP can often be managed on an outpatient basis, aTTP requires intensive treatment and immediate hospitalization.” This distinction is crucial for the proper management of patients, as aTTP is a condition that can rapidly worsen a patient’s health if not treated immediately.
The emotional impact of living with ITP
Beyond the physical implications, living with this condition carries a significant emotional burden. Once diagnosed, it presents numerous emotional challenges for patients. “The initial diagnosis is often accompanied by a great deal of uncertainty,” says Dr. Pascual. “Patients are often constantly worried about their platelet counts and fear that this condition might be a precursor to more serious diseases, such as leukemia.” This concern is not unfounded, as hematological diseases can share overlapping symptoms. Furthermore, the lack of a definitive cure forces patients to accept the disease as a chronic condition they will have to live with for the rest of their lives. This process of acceptance can be difficult and very lengthy, affecting not only the patient but also their family and social circle.
Physical challenges: beyond obvious bleedings
In terms of physical symptoms, patients with this condition experience a variety of manifestations, ranging from small bruises and petechiae (red spots on the skin) to nosebleeds or bleeding gums. However, what truly surprises doctors is that many patients also report intense and unexplained fatigue. “This fatigue is a recurring complaint among patients, although we do not fully understand its origin from a scientific standpoint,” reveals Dr. Pascual. “It’s frustrating for both patients and doctors, since we don’t have a clear explanation for this symptom, which makes managing the disease even more difficult.” This constant exhaustion significantly affects patients’ quality of life, limiting their ability to perform daily activities and maintain an adequate energy level.
Living with the disease: continuous monitoring and support
The treatment and management of this disease require a personalized approach, especially in the early stages of diagnosis. Dr. Pascual explains that “in the early stages, we see patients every week or every ten days, depending on their platelet count, until they reach a safer level.” This close monitoring is essential to prevent serious complications, such as internal bleeding, which can be life-threatening. In addition, first-line treatment for ITP generally includes steroids, which help reduce immune system activity and increase platelet counts. If steroids are not effective, doctors may turn to other treatment options, such as immunoglobulins or more aggressive immunosuppressive therapies.
Alongside medical treatment, emotional support and education about the disease are essential to helping patients adapt to their new reality. Dr. Pascual emphasizes the importance of community and mutual support: “There are support groups and associations that are of great help to patients, as they allow them to better understand their condition and share their experiences with others who are going through the same thing.” In this regard, the Spanish Immune Thrombocytopenia Group (GEPTI), of which Dr. Pascual is president, plays a crucial role. This organization is not only dedicated to the study and research of the condition but also organizes conferences and talks for patients. These events provide a safe space where patients can learn more about their condition, access up-to-date information, and hear the experiences of others facing similar challenges. By fostering this sense of community, GEPTI helps alleviate the emotional burden of the disease and offers patients valuable tools to cope with it.
Hope and future prospects for patients
Despite the many challenges posed by this condition, there are reasons for optimism. “PTI is not a death sentence,” Dr. Pascual states firmly. “With proper treatment and constant monitoring, most patients can lead a relatively normal life.” This message of hope is crucial for newly diagnosed patients, who often feel overwhelmed by uncertainty and fear of the future. The possibility of living a full life—albeit with certain limitations—is a source of relief for many.
In addition, the creation of patient associations and the increasingly comprehensive approach to treatment are positive signs of progress. “We’re seeing a shift in the way doctors approach the condition,” says Dr. Pascual. “Now we’re more concerned with what patients think and feel, and not just with the numbers in their blood tests.” This shift in focus is essential for improving patients’ quality of life, as it addresses not only the physical aspects of the disease but also its emotional and psychological impact.
In conclusion, we would like to emphasize that immune thrombocytopenia is a complex disease that goes beyond the visible physical symptoms. It profoundly affects the emotional well-being and quality of life of those who suffer from it. However, with the right support, personalized treatment and a comprehensive approach, patients can learn to live with ITP, facing their daily challenges with resilience and looking to the future with hope. The work of organizations like GEPTI and the dedication of professionals like Dr. Cristina Pascual are critical to improving patients' lives, providing not only medical care, but also emotional and community support that is equally vital.
